Clovis Plans Rucaparib Commercial Launch, After Abandoning Rociletinib
This article was originally published in The Pink Sheet Daily
Executive Summary
In light of FDA’s plan to issue a complete response letter, Clovis ends development of next-gen EGFR inhibitor rociletinib to save cash and refocuses on approval and launch of PARP inhibitor rucaparib for ovarian cancer.